AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
samidorphan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| opioid receptor antagonists/agonists, morphinan derivates | 5460 | 852626-89-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Samidorphan was first approved in combination with olanzapine by the FDA on May 28, 2021, under the name LYBALVI. The mechanism of action of samidorphan could be mediated through opioid receptor antagonism.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
| BA (Bioavailability) | 69 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,CAMK2D,CDK5,EIF2AK3,GRK2,ITK,MAPK7,PDK1,PDK2,PRKDC | 10 | |||
| kinase-selectivity-class | AXL,EIF2AK3,GRK2,MAP2K6,MAP3K14,TEK | 6 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 28, 2021 | FDA | ALKERMES INC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05AH53 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Diazepines, oxazepines, thiazepines and oxepines |
| FDA MoA | N0000000154 | Opioid Antagonists |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014149 | Tranquilizing Agents |
| MeSH PA | D014150 | Antipsychotic Agents |
| MeSH PA | D009292 | Narcotic Antagonists |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018689 | Sensory System Agents |
| FDA EPC | N0000175691 | Opioid Antagonist |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
Related Drugs by ATC class:
N05AH Diazepines, oxazepines, thiazepines and oxepines 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Schizophrenia | indication | 58214004 | DOID:5419 |
| Bipolar I disorder | indication | 371596008 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 10716785 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 10716785 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11185541 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11241425 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11351166 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11351166 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11793805 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA IN A PATIENT WHO HAS PREVIOUSLY EXPERIENCED SIGNIFICANT WEIGHT GAIN INDUCED BY OLANZAPINE ALONE BY ADMINISTERING A COMPOSITION COMPRISING OLANZAPINE AND SAMIDORPHAN |
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 12194035 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 9126977 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 9126977 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 9517235 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE |
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 9517235 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 10716785 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 10716785 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11185541 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11241425 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11351166 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11351166 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11793805 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA IN A PATIENT WHO HAS PREVIOUSLY EXPERIENCED SIGNIFICANT WEIGHT GAIN INDUCED BY OLANZAPINE ALONE BY ADMINISTERING A COMPOSITION COMPRISING OLANZAPINE AND SAMIDORPHAN |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 12194035 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 9126977 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 9126977 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 9517235 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 9517235 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 10716785 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 10716785 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11185541 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11241425 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11351166 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11351166 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11793805 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA IN A PATIENT WHO HAS PREVIOUSLY EXPERIENCED SIGNIFICANT WEIGHT GAIN INDUCED BY OLANZAPINE ALONE BY ADMINISTERING A COMPOSITION COMPRISING OLANZAPINE AND SAMIDORPHAN |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 12194035 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 9126977 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 9126977 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 9517235 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 9517235 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 10716785 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 10716785 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11185541 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11241425 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11351166 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11351166 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11793805 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA IN A PATIENT WHO HAS PREVIOUSLY EXPERIENCED SIGNIFICANT WEIGHT GAIN INDUCED BY OLANZAPINE ALONE BY ADMINISTERING A COMPOSITION COMPRISING OLANZAPINE AND SAMIDORPHAN |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 12194035 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 9126977 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 9126977 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 9517235 | Aug. 23, 2031 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 9517235 | Aug. 23, 2031 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE |
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 8778960 | Feb. 13, 2032 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 8778960 | Feb. 13, 2032 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 8778960 | Feb. 13, 2032 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 8778960 | Feb. 13, 2032 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 8778960 | Feb. 13, 2032 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 8778960 | Feb. 13, 2032 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 8778960 | Feb. 13, 2032 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 8778960 | Feb. 13, 2032 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN |
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 10300054 | May 31, 2033 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 10300054 | May 31, 2033 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 10300054 | May 31, 2033 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 10300054 | May 31, 2033 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 10300054 | May 31, 2033 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 10300054 | May 31, 2033 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 10300054 | May 31, 2033 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 10300054 | May 31, 2033 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN |
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11951111 | Nov. 12, 2041 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING A BILAYER TABLET COMPRISING OLANZAPINE AND SAMIDORPHAN |
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11951111 | Nov. 12, 2041 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING A BILAYER TABLET COMPRISING OLANZAPINE AND SAMIDORPHAN |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11951111 | Nov. 12, 2041 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING A BILAYER TABLET COMPRISING OLANZAPINE AND SAMIDORPHAN |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11951111 | Nov. 12, 2041 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING A BILAYER TABLET COMPRISING OLANZAPINE AND SAMIDORPHAN |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11951111 | Nov. 12, 2041 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING A BILAYER TABLET COMPRISING OLANZAPINE AND SAMIDORPHAN |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11951111 | Nov. 12, 2041 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING A BILAYER TABLET COMPRISING OLANZAPINE AND SAMIDORPHAN |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11951111 | Nov. 12, 2041 | METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING A BILAYER TABLET COMPRISING OLANZAPINE AND SAMIDORPHAN |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | 11951111 | Nov. 12, 2041 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING A BILAYER TABLET COMPRISING OLANZAPINE AND SAMIDORPHAN |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 10MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | May 28, 2026 | NEW CHEMICAL ENTITY |
| 15MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | May 28, 2026 | NEW CHEMICAL ENTITY |
| 20MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | May 28, 2026 | NEW CHEMICAL ENTITY |
| 5MG;EQ 10MG BASE | LYBALVI | ALKERMES INC | N213378 | May 28, 2021 | RX | TABLET | ORAL | May 28, 2026 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Mu-type opioid receptor | GPCR | ANTAGONIST | Ki | 10.28 | DRUG LABEL | ||||
| Kappa-type opioid receptor | GPCR | PARTIAL AGONIST | Ki | 9.64 | DRUG LABEL | ||||
| Delta-type opioid receptor | GPCR | PARTIAL AGONIST | Ki | 8.59 | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| D10162 | KEGG_DRUG |
| 7W2581Z5L8 | UNII |
| 1204592-75-5 | SECONDARY_CAS_RN |
| C4277369 | UMLSCUI |
| CHEBI:177605 | CHEBI |
| CHEMBL426084 | ChEMBL_ID |
| 11667832 | PUBCHEM_CID |
| DB12543 | DRUGBANK_ID |
| CHEMBL2105749 | ChEMBL_ID |
| 9515 | INN_ID |
| C000606131 | MESH_SUPPLEMENTAL_RECORD_UI |
| C000722611 | MESH_SUPPLEMENTAL_RECORD_UI |
| C583425 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10651 | IUPHAR_LIGAND_ID |
| 4040827 | VANDF |
| 347116 | MMSL |
| 39562 | MMSL |
| d09753 | MMSL |
| 018753 | NDDF |
| 2559612 | RXNORM |
| 7W2581Z5L8 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| LYBALVI | HUMAN PRESCRIPTION DRUG LABEL | 2 | 65757-651 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 29 sections |
| LYBALVI | HUMAN PRESCRIPTION DRUG LABEL | 2 | 65757-652 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 29 sections |
| LYBALVI | HUMAN PRESCRIPTION DRUG LABEL | 2 | 65757-653 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 29 sections |
| LYBALVI | HUMAN PRESCRIPTION DRUG LABEL | 2 | 65757-654 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 29 sections |